# Batlivala & Karani

# RESULT UPDATE MID CAP

# Share Data

Reuters code SI					
Bloomberg code					
Market cap. (US\$ mn)					
6M avg. daily turnover (US\$ mn)					
Issued shares (mn)					
Target price (Rs)					
1 <b>M</b>	<b>3M</b>	12M			
47	66	87			
46	48	56			
	ver (US 1M 47	rer (US\$ mn) <b>1M 3M</b> 47 66			

#### Valuation ratios

Yr to 31 Mar	FY11E	FY12E
EPS (Rs)	61.3	75.5
+/- (%)	19.9	23.1
PER(x)	6.6	5.3
PBV (x)	1.6	1.3
Dividend/Yield (%)	3.5	3.5
EV/Sales (x)	1.1	0.9
EV/EBITDA(x)	4.4	3.5
Major shareholde	ers (%)	
Promoters		47
FIIs		10
MFs		10
BFSI's		2

31

#### **Financial highlights**

Public & Others

# SRF



27 October 2010

#### **Maintain Outperformer**

Duriana Da 102	DEE Indom 20 221
Price: Rs 402	<b>BSE Index: 20,221</b>

## 2QFY11 Result - Excellent core business growth sans CERs

SRF's results were in line with our expectations. The company registered an impressive ~42% YoY revenue growth. The packaging film business (PFB) proved to be the key growth driver, benefiting from the capacity expansion and the prevailing robust demand. The significant improvement in BOPET film realisations both on a YoY and QoQ basis further boosted the segment's profitability. The technical textile business (TTB) revenue grew steadily, however the segment margins declined. This was due to the addition of new capacities in lamination films and polyester tyre cord which are yet to stabilise. The company has not booked CERs during the quarter. The chemical business (CB) segment witnessed strong performance in spite of the absence of CERs. Both the refrigerant gas and flouro specialty chemicals have done exceedingly well on the back of strong volume growth and robust realisations. Though the segment margins have declined marginally both on a YoY and QoQ basis, the current margin of ~38% is enough to add significantly to the company's net profit. The company expects to maintain the CB segment margins between 30-35% levels.

The company has terminated some CER contracts during the quarter and has received ~Rs 480 mn arising out of the forward contract termination (included in the net sales). This trend may continue in the next quarter too. The uncertainty over the CER realisations still prevails. Recently, some new methodologies have been suggested by a UN panel for determining the quantum of CERs. The norms are becoming stringent and the approval process has got elongated. Therefore we are cautious on the contribution of CERs in the near term.

( <b>Rs mn</b> )	2QFY10	2QFY11	<b>YoY</b> (%)	1HFY10	1HFY11	YoY (%)	FY10	FY11E	YoY (%)	FY12E	YoY (%)
Net Income from operations	5,267	7,482	42.1	10,246	13,672	33.4	21,811	28,810	32.1	36,151	25.5
EBITDA	1,519	2,138	40.7	3,076	3,428	11.4	5,851	7,593	29.8	9,503	25.2
EBITDA Margin (%)	28.8	28.6	_	30.0	25.1	_	26.8	26.4	_	26.3	_
Other Income	14.2	18.0	26.8	37.2	75.6	103.2	682	287	(57.9)	192	(33.1)
Interest	156	205	31.3	301	401	33.3	680	806	18.4	884	9.8
Depreciation	320	381	19.1	608	748	23.0	1,313	1,536	17.0	1,992	29.7
РВТ	1,057	1,570	48.5	2,204	2,354	6.8	4,539	5,538	22.0	6,819	23.1
Extraordinary item/ forex gain (loss)	(27)	158	—	(206)	(179)	_	_	_	—	_	—
Tax	344	514	49.2	799	772	(3.4)	1,445	1,827	26.5	2,250	23.1
Reported PAT	686	1,214	77.0	1,200	1,404	17.0	3,094	3,710	19.9	4,568	23.1
Adjusted PAT	713	1,056	48.1	1,406	1,583	12.6	3,094	3,710	19.9	4,568	23.1
Adjusted PAT margin (%)	13.5	14.1	—	13.7	11.6	—	14.2	12.9	_	12.6	_
Adjusted EPS (Rs)	11.8	17.5	48.1	23.2	26.2	12.6	51.1	61.3	19.9	75.5	23.1

In our opinion, the impressive performance of CB segment sans CERs bodes well for the long-term growth. This will also lessen the impact of CERs on the net earnings and hence provide better clarity on the core chemical business.

The PFB segment is witnessing strong demand. New applications such as thin films for LCD panels, thick films for fashion garments, coupled with the increase in the demand from existing customer segments is driving the segment.

#### **Outlook and valuation**

The strong demand momentum and the improved pricing in CB and PFB segments will drive the growth and profitability in future. In TTB segment, stabilisation of new capacities may improve the margins slightly. In the wake of robust improvement in the CB and PFB business, we have increased our revenue and earnings estimate for FY11 and FY12.

At the current market price of Rs 402, the stock trades at 6.6x FY11E and 5.3x FY12E, revised earnings, respectively. We have arrived at the SOTP value of Rs 466 per share considering the revised FY12 estimates and maintain an Outperformer rating on the stock.

#### 2QFY11 segmental highlights

( <b>Rs mn</b> )	2QFY10	2QFY11	<b>YoY</b> (%)	1HFY10	1HFY11	YoY (%)
Revenues						
TTB	3,044	3,553	16.7	5,600	6,925	23.7
CB	1,564	1,805	15.4	3,313	3,086	(6.8)
PFB	675	2,139	216.9	1,342	3,687	174.9
Less: Inter-segment revenues	16	15	(5.6)	26	27	_
Total	5,267	7,482	42.1	10,229	13,672	33.7
EBIT						
TTB	642	336	(47.6)	991	733	(26.1)
CB	606	675	11.3	1,488	1,167	(21.5)
PFB	47	890	1,805.8	164	1,197	629.1
Total	1,295	1,901	46.8	2,643	3,097	17.2
Interest	156	205	31.3	301	401	33.3
Unallocable expenditure	108	(32)	(129.3)	(68)	163	(338.4)
PBT	1,030	1,728	67.7	2,410	2,533	5.1
Capital employed						
ТТВ	12,096	11,757	(2.8)	12,096	11,757	(2.8)
CB	4,794	5,283	10.2	4,794	5,283	10.2
PFB	1,686	4,642	175.2	1,686	4,642	175.2
Capital WIP	2,315	680	(70.6)	2,315	680	(70.6)
Add: Unallocable asset less liab	ilities 2,052	1,456	(29.1)	2,052	1,456	(29.1)
Total	22,943	23,817	3.8	22,943	23,817	3.8
EBIT margins (%)						
TTB	21.1	9.5	_	17.7	10.6	_
CB	38.8	37.4	_	44.9	37.8	-
PFB	6.9	41.6	_	12.2	32.5	-
<b>RoCE</b> (%)						
TTB	5.3	2.9	_	8.2	6.2	_
CB	12.6	12.8	_	31.0	22.1	_
PFB	2.8	19.2	_	9.7	25.8	_
Revenue mix (%)						
ТТВ	57.8	47.5	_	54.8	50.7	_
CB	29.7	24.1	_	32.4	22.6	—
PFB	12.8	28.6	_	13.1	27.0	_

## New initiatives

The company has capitalised 61,000 MTPA polyester chip plant for PFB segment during the quarter. It is also setting up a polyester film plant in Bangladesh in a joint venture with Nitol-Niloy group having an initial capacity of 28,500 MTPA. SRF will hold 80% stake in the JV and total project cost is estimated to be ~US\$ 65 mn. SRF is also setting up new units for flouro specialty chemicals at Dahej at the estimated cost of Rs 2 bn. These new projects are expected to come on stream in FY13. The new initiatives will further strengthen the company's position in the respective segments.

## **B&K RESEARCH**

Income Statement					
Yr end 31 Mar (Rs m	n) FY09	FY10	FY11E	FY12E	
Net Sales	18,008	21,811	28,810	36,151	
Growth (%)	11.0	21.0	32.0	25.0	
Operating Expenses	(13, 415)	(15, 960)	(21, 217)	(26,648)	
Operating Profit	4,593	5,851	7,593	9,503	
EBITDA	4,593	5,851	7,593	9,503	
Growth (%)	36.5	27.4	29.8	25.2	
Depreciation	(994)	(1, 313)	(1, 536)	(1,992)	
Other Income	(628)	682	287	192	
EBIT	2,971	5,219	6,343	7,703	
Interest Paid	(511)	(680)	(806)	(884)	
Pre-tax profit	2,460	4,539	5,538	6,819	
(before non-recurring iter	ns)				
Pre-tax profit	2,460	4,539	5,538	6,819	
(after non recurring items	3)				
Tax (current + deferred)	(827)	(1, 445)	(1, 827)	(2,250)	
Net Profit	1,633	3,094	3,710	4,568	
Reported PAT	1,633	3,094	3,710	4,568	
Adjusted net profit	1,633	3,094	3,710	4,568	
Growth (%)	17.7	89.5	19.9	23.1	

Balance Sheet				
Yr end 31 Mar (Rs mn)	FY09	FY10	FY11E	FY12E
Current assets	5,712	8,219	10,247	12,906
Cash & marketable securiti	es 31	653	1,298	1,672
Other current assets	5,681	7,566	8,949	11,234
Investments	1,336	1,646	1,646	1,646
Net fixed assets	16,604	18,988	20,681	21,689
Total assets	23,653	28,853	32,575	36,241
Current liabilities	3,307	4,721	5,525	5,917
Total debt	8,848	9,393	9,893	9,893
Other non-current liabilities	1,733	2,059	2,059	2,059
Total liabilities	13,888	16,173	17,478	17,870
Share capital	617	615	615	615
Reserves & surplus	9,148	12,065	14,481	17,756
Shareholders' funds	9,765	12,680	15,097	18,371
Total equity & liabilities	23,653	28,853	32,575	36,241
Capital employed	20,346	24,132	27,049	30,324

Cash Flow Stateme	ent			
Yr end 31 Mar (Rs mn	) <b>FY09</b>	FY10	FY11E	FY12E
Pre-tax profit	2,460	4,539	5,538	6,819
Depreciation	(1,000)	(1, 321)	(1,536)	(1,992)
Chg in working capital	38	(541)	(1, 570)	(1,893)
Total tax paid	(515)	(1,048)	(1, 827)	(2, 250)
Cash flow from oper. (a	a) 2,983	4,271	3,676	4,668
Capital expenditure	(5, 136)	(3, 655)	(3, 229)	(3,000)
Chg in investments	139	(310)	0	0
Other investing activities	(302)	(303)	(303)	(302)
Others	(112)	(50)	0	0
Cash flow from inv. (b)	(5,411)	(4,318)	(3,532)	(3,303)
Free cash flow (a+b)	(2,429)	(46)	144	1,365
Equity raised/(repaid)	(757)	(17)	0	0
Debt raised/(repaid)	3,862	545	500	0
Dividend (incl tax.)	(925)	(991)	(6)	(991)
Cash flow from fin. (c)	2,387	669	500	(991)
Net chg in cash (a+b+c	) (41)	622	644	374

Key Ratios				
Yr end 31 Mar (%)	FY09	FY10	FY11E	FY12E
Adjusted EPS (Rs)	27.0	51.1	61.3	75.5
Growth	32.1	89.5	19.9	23.1
Book NAV/Share (Rs)	161.3	209.5	249.4	303.6
Dividend/Share (Rs)	10.3	14.0	14.0	14.0
Dividend payout ratio	44.8	32.0	26.7	21.7
Tax	33.6	31.8	33.0	33.0
EBITDA margin	25.5	26.8	26.4	26.3
EBIT margin	16.5	23.9	22.0	21.3
RoCE	16.3	23.5	24.8	26.9
Net debt/Equity	90.3	68.9	56.9	44.8

Valuations				
Yr end 31 Mar (x)	FY09	FY10	FY11E	FY12E
PER	14.9	7.9	6.6	5.3
PCE	9.3	5.5	4.6	3.7
Price/Book	2.5	1.9	1.6	1.3
Yield (%)	2.6	3.5	3.5	3.5
EV/Net sales	1.8	1.5	1.1	0.9
EV/EBITDA	7.2	5.7	4.4	3.5

Γ


Du Pont Analysis – ROE					
Yr end 31 Mar (x)	FY09	FY10	FY11E	FY12E	
Net margin (%)	9.1	14.2	12.9	12.6	
Asset turnover	0.8	0.8	0.9	1.1	
Leverage factor	2.2	2.3	2.2	2.1	
Return on equity (%)	16.8	27.6	26.7	27.3	

October 2010

Anurag Randev anurag.randev@bksec.com +91-120-460 5617 Shweta Mungre shweta.mungre@bksec.com +91-120-460 5620

**Analyst Declaration:** We, Anurag Randev & Shweta Mungre, hereby certify that the views expressed in this report accurately reflect our personal views about the subject securities and issuers. We also certify that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendation or view expressed in this report.

#### **B&K Universe Profile**



#### B&K Securities is the trading name of Batlivala & Karani Securities India Pvt. Ltd.

#### **B&K Investment Ratings:**

1. **BUY:** Potential upside of > +25% (absolute returns)

0 to +25%

- 2. OUTPERFORMER:
- 3. UNDERPERFORMER: 0 to -25%
- 4. **SELL:** Potential downside of < -25% (absolute returns)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, print, publishing, photocopying, recording or otherwise without the permission of Batlivala & Karani Securities India Pvt. Ltd. Any unauthorized act in relation to all or any part of the material in this publication may call for appropriate statutory proceedings.

The information contained herein is confidential and is intended solely for the addressec(s). Any unauthorized access, use, reproduction, disclosure or dissemination is prohibited. This information does not constitute or form part of and should not be construed as, any offer for sale or subscription of or any invitation to offer to buy or subscribe for any securities. The information and opinions on which this communication is based have been complied or arrived at from sources believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, correctness and are subject to change without notice. Batlivala & Karani Securities India P Ltd and/ or its clients may have positions in or options on the securities mentioned in this report or any related investments, may effect transactions or may buy, sell or offer to buy or sell such securities or any related investments. Recipient/s should consider this report only for secondary market investments and as only a single factor in making their investment decision. The information enclosed in the report has not been vetted by the compliance department due to the time sensitivity of the information/document. Some investments discussed in this report have a high level of volatility. High volatility investments may experience sudden and large falls in their value causing losses when the investment is realized. Those losses may equal your original investment. Some investments may not be readily realizable and it may be difficult to sell or realize those investments, similarly it may prove difficult for you to obtain reliable information about the value, risks to which such an investment is exposed. Neither B&K Securities nor any of its affiliates shall assume any legal liability or responsibility for any incorrect, misleading or altered information contained herein.

#### **B & K SECURITIES INDIA PRIVATE LTD.**

Equity Research Division: City Ice Bldg, 298, Ground/1st Floor, Perin Nariman Street, Behind RBI, Fort, Mumbai - 400 001, India. Tel.: 91-22-4031 7000, Fax: 91-22-2263 5020/30. Registered Office: Room No. 3/4, 7 Lyons Range, Kolkata - 700 001. Tel.: 91-33-2243 7902.

#### B&K Research is also available on Bloomberg <BNKI>, Thomson First Call & Investext.